Q4 2024 Pharma Mar SA Earnings Call Transcript
Key Points
- Pharma Mar SA (PHMMF) reported double-digit revenue growth for 2024, driven primarily by strong sales of Sasea and Yanelli.
- The company achieved an 18% growth in total royalty revenues, with significant contributions from the US market.
- Net profit surged to €26 million in 2024, reflecting robust financial performance and positive tax gains.
- Pharma Mar SA (PHMMF) maintains a strong financial position with net cash over €100 million, providing a solid foundation for future growth.
- Significant progress in clinical trials, including positive results from the phase 3 trial for small cell lung cancer, with plans to submit a marketing authorization application to the EMA.
- Sales of Joellis declined in its second full year of coexistence with generics, impacting overall revenue growth.
- R&D expenses increased by 4% year-on-year, which could pressure margins if not offset by revenue growth.
- The company faces challenges in business development, with high asset prices and a lengthy process for acquiring late-stage or commercial-stage assets.
- Uncertainty remains regarding the approval timeline for new drugs, as it depends on regulatory bodies like the EMA and FDA.
- No decision has been made yet regarding the dividend for the year, which may concern investors looking for returns.
Good afternoon and welcome to the Farm Arar Full yearear Results 2024 conference call. My name is Charlie and I'll be coordinating the call today.
If you'd like to ask a question at the end of the presentation, you can do so by pressing followed by one on your telephone keypads. I shall now hand over to our host, Jose Luis Moreno, Vice President, head of capital markets and investor relations to begin. Jose, please go ahead.
Thank you, Charlie, and good morning to everyone.
Thank you for joining today's far endings conference call for the financial results for the year 24.
And the call with me today are Maria Lua Efrancia, Chief Financial Officer of PAMA.
Luis Murra, managing director of Parma, and Pascal Basman, senior Vice President of strategic Development.
Following our prepared remarks today, we'll open the line for questions and I would like to remind you that today's conference call might include forward-looking
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
